Resmed (RSMDF) EBIAT (2016 - 2025)
Historic EBIAT for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $392.6 million.
- Resmed's EBIAT rose 1391.99% to $392.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 1899.33%. This contributed to the annual value of $1.4 billion for FY2025, which is 3719.79% up from last year.
- Resmed's EBIAT amounted to $392.6 million in Q4 2025, which was up 1391.99% from $348.5 million recorded in Q3 2025.
- Resmed's EBIAT's 5-year high stood at $392.6 million during Q4 2025, with a 5-year trough of -$78.5 million in Q1 2021.
- In the last 5 years, Resmed's EBIAT had a median value of $227.3 million in 2022 and averaged $247.8 million.
- In the last 5 years, Resmed's EBIAT plummeted by 14810.74% in 2021 and then skyrocketed by 32809.6% in 2022.
- Quarter analysis of 5 years shows Resmed's EBIAT stood at $201.8 million in 2021, then increased by 11.48% to $224.9 million in 2022, then decreased by 7.16% to $208.8 million in 2023, then soared by 65.05% to $344.6 million in 2024, then rose by 13.92% to $392.6 million in 2025.
- Its last three reported values are $392.6 million in Q4 2025, $348.5 million for Q3 2025, and $379.7 million during Q2 2025.